IBX's IND Application Lodged with FDA for HER2 Phase 2 Trial

➢ Imagion Biosystems has lodged its Investigational New Drug (IND) application for the MagSense® HER2 Imaging Agent to the U.S. Food and Drug Administration (FDA) ➢ IND Submission marks a major milestone in the clinical development of the company’s proprietary MagSense® platform ➢ Phase 2 Clinical Trial enrollment planned to commence following FDA approval ➢ Strategic trial partners engaged, study